D‐dimer enhances risk‐targeted thromboprophylaxis in ambulatory patients with cancer

V Kumar, JR Shaw, NS Key, A Ilich, R Mallick… - The …, 2020 - academic.oup.com
Background Thromboprophylaxis for ambulatory patients with cancer is effective, although
uncertainties remain on who should be targeted. Using D‐dimer values from individuals …

[HTML][HTML] Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

AS Mansfield, AJ Tafur, CE Wang, TV Kourelis… - Journal of Thrombosis …, 2016 - Elsevier
Essentials• Venous thromboembolism (VTE) prevention strategies require effective risk
assessment models.• We sought to validate the Khorana Risk Score (KRS) in patients with …

Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States

AA Khorana, M Dalal, J Lin, GC Connolly - Cancer, 2013 - Wiley Online Library
BACKGROUND: Recent studies suggest that thromboprophylaxis is beneficial in preventing
venous thromboembolism (VTE) in cancer outpatients, but this is not widely adopted …

Venous thromboembolism and prophylaxis in cancer patients

S Paškauskas, J Pundzius, G Barauskas - Medicina, 2008 - mdpi.com
Venous thromboembolism is a serious complication in patients with cancer. The seriousness
of venous thromboembolism as a complication in cancer patients is becoming recognized as …

Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI)

AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj… - 2018 - ashpublications.org
Background: Patients on systemic therapy for cancer are at varying risk for venous
thromboembolism (VTE) and its consequences. Thromboprophylaxis is recommended in …

Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy

NM Kuderer, CW Francis, E Culakova… - Journal of Clinical …, 2008 - ascopubs.org
9521 Background: Venous thromboembolism (VTE) is a common complication of cancer
occurring with increasing frequency. A recent meta-analysis of anticoagulation as a form of …

[HTML][HTML] Risk assessment models of cancer-associated thrombosis-potentials and perspectives

F Moik, C Englisch, I Pabinger, C Ay - Thrombosis Update, 2021 - Elsevier
Patients with cancer are at increased risk of venous thromboembolism (VTE). Risk
assessment models can help identifying high-risk populations that might benefit from …

[HTML][HTML] Incidence of venous thromboembolism in patients with cancer–a cohort study using linked United Kingdom databases

AJ Walker, TR Card, J West, C Crooks… - European journal of …, 2013 - Elsevier
BACKGROUND: Accurate population-based data are needed on the incidence of venous
thromboembolism (VTE) in patients with different cancers in order to inform guidelines on …

[HTML][HTML] Clinical guide SEOM on venous thromboembolism in cancer patients

AJ Muñoz Martín, C Font Puig… - Clinical and …, 2014 - Springer
Venous thromboembolism (VTE) is a common event in cancer patients and one of the major
causes of cancer-associated mortality and a leading cause of morbidity. In recent years, the …

A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective …

A Muñoz, C Ay, E Grilz, S López, C Font… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …